Docteur FABIENNE LE GUILCHARD

Bibliographie

• Methotrexate effect on immunogenicity and long-term maintenance of adalimumab in axial spondyloarthritis: a multicentric randomised trial

  2020

  ArticleRMD Open : Rheumatic & Musculoskeletal Diseases

Source : HAL — archive ouverte CCSD/CNRS (couvre articles, chapitres EMC, communications congrès, thèses).

Lieu de consultation

• CH BLOIS SIMONE VEIL

  Mail PIERRE CHARLOT, 41016 Blois

  ☎ 0254556633Hospitalier🏥 Centre CH ↗🏥 Voir cet établissement

Tarifs & secteur de conventionnement

Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).

Prendre rendez-vous & contact

Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).

Articles de presse (4)

Source : Google News (recherche par nom complet — homonymes possibles, vérifier le contenu).

• Le Guilchard, atout coeur - lanouvellerepublique.fr

  📰 lanouvellerepublique.fr · 30/09/2016

  <a href="https://news.google.com/rss/articles/CBMipwFBVV95cUxQdnlrUEQ3MFN6cnJFQWlEbF9ldW1tWGN1RUxkQWJEWVo5LU5EQmxlUkpTbDloMmRiRjVyeC13MzFhNVNyTG92dThURDhEN1dlY0xQNVgtWW9QSGNoWnJtdFNSRU1GWUtVWVIycU5oSEI1MC14LVBudFBRb3Jjdl9vbFRTTy1ZVXg2WHpQUjVCZWNhV1VxOTd1NHpBdzBOemR0MUVwTTVObw?oc=5" target="_blank">L

• Diagnostic, suivi et intervention avec l'échographie ostéo-articulaire - lanouvellerepublique.fr

  📰 lanouvellerepublique.fr · 10/12/2014

  <a href="https://news.google.com/rss/articles/CBMiugFBVV95cUxPazRVUThHRTVaZjkydnMyaGFrNFFHX09uTDQxZnFNUF83R3JMemJuSlBLeV9fQ2VVZ0YxVEN0Tlk1VlEzS1kzMUFYam5yNnZ4bTRmNnBpVnVoSXZtMHJGa1U0akJiRTZQdEZCWVFPZDQ1TndEWlJUZGJsUUlMLUs3V0hLbGdGVXpfbWtoTzdqZ3J1cjZhNlBFOGszTlZSdEtabGNBOFdXSTRKS1Y5SnBkWDc2ZVJDQVBQZ2

• Quand la sécurité des patients pose question - lanouvellerepublique.fr

  📰 lanouvellerepublique.fr · 29/11/2013

  <a href="https://news.google.com/rss/articles/CBMimAFBVV95cUxNcW9TOHBnOHh2QlBMYmhuTnE5LVU2TVR5clk2LVE5UXJtT3g3ejFLcUNnVVAtUzN3VzRQaVhSMkExWGN1dGM2OS1lUDZnaV90anppdVBpeGpjWEhKQUhCX2pDbnI0cGZvZWdGdE5YS1FYR3Vkc21uMmJPR0hRb25meTJyQ0lhVjQxTVkzUmxWQXVVTmFBUzdMMQ?oc=5" target="_blank">Quand la sécurité des

• L'ostéoporose se détecte à l'hôpital de Blois - lanouvellerepublique.fr

  📰 lanouvellerepublique.fr · 14/12/2011

  <a href="https://news.google.com/rss/articles/CBMimgFBVV95cUxOanBtQVlMd2FZQUlIV3RfcDh0MmRDeGM0SldqandKYld1R0xEU3lEdGtoYVVxUkEtbzN3Z0FGRXR3Ym13REpGckdMUlVvWXpZdDZGTnpVQkh5VGhfYU1Vdk1WY3RfWHRtWGRDSHg2ZG9Qa2NiZkkzS24tbVZEVWlIRTJiVGMyMnhaY1J0cnNPcVBJTldUM1RENmR3?oc=5" target="_blank">L'ostéoporose se dé

Top publications · les plus citées

• 1

  Methotrexate effect on immunogenicity and long-term maintenance of adalimumab in axial spondyloarthritis: a multicentric randomised trial

  RMD open · 2020

  📚 46 citations🎯 RCR 3.11Top 15% NIH🩺 Clinique🔓 Open Access📄 PDF gratuit ↗

  Lire l'abstract Crossref ↓

  Objectives Anti-drug antibodies (ADA) are responsible for decreased adalimumab efficacy in axial spondyloarthritis (SpA). We aimed to evaluate the ability of methotrexate (MTX) to decrease adalimumab immunisation. Methods A total of 110 patients eligible to receive adalimumab 40 mg subcutaneously (s.c.) every other week were randomised (1:1 ratio) to receive, 2 weeks before adalimumab (W-2) and weekly, MTX 10 mg s.c. (MTX+) or not (MTX−). ADA detection and adalimumab serum concentration were assessed at weeks 4 (W4), 8 (W8), 12 (W12) and 26 (W26) after starting adalimumab (W0). The primary outcome was the proportion of patients with ADA at W26. Four years after the study completion, we retrospectively analysed adalimumab maintenance in relation with MTX co-treatment duration. Results We analysed data for 107 patients (MTX+; n=52; MTX-; n=55). ADA were detected at W26 in 39/107 (36.4%) patients: 13/52 (25%) in the MTX+ group and 26/55 (47.3%) in the MTX− group (p=0.03). Adalimumab concentration was significantly higher in the MTX+ than MTX− group at W4, W8, W12 and W26. The two groups did not differ in adverse events or efficacy. In the follow-up study, MTX co-treatment &gt;W26 versus no MTX or ≤W26 was significantly associated with adalimumab long-term maintenance (p=0.04). Conclusion MTX reduces the immunogenicity and ameliorate the pharmacokinetics of adalimumab in axial SpA. A prolonged co-treatment of MTX&gt;W26 seems to increase adalimumab long-term maintenance.

• 2

  Rheumatoid nodules in systemic lupus erythematosus: a case report

  Joint bone spine · 2003

  📚 6 citations
• 3

  Delayed pressure urticaria in a patient with ulcerative colitis

  Joint bone spine · 2002

  📚 1 citations

Publications scientifiques (3) — classées par pathologie

Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).

Partager cette fiche